ABATTIS LEADING WITH EXPERTISE
By aligning with ABLE BC, Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF) set itself at the forefront of the commercial cannabis rollout. As part of the deal, Abattis is expected to provide its technical expertise, in terms of quality assurance over dosages, terpene analysis, potency, etc.
Among Abattis’s subsidiaries, and key to the agreement, is its laboratory located in BC, which is a leader in extraction, and testing and analysis.
For consumers and vendors alike, quality assurances are going to be extremely important.
So Abattis’s role beyond supplying products to be sold in these licensed locations will be in educating vendors, and providing testing and inspection issues such as:
– potency and cannabinoid profile;
– microbiological screening;
– pesticide and heavy metal testing;
– terpene analysis;
– and residual solvent testing.
“We foresee this partnership in the cannabis industry a key part of our future. We feel that testing services provided by Abattis will give us the peace of mind that consumers require regarding dosage quality and safety” said Jeff Guignard, Executive Director of ABLE BC.
Another part of Abattis’s network is that of wholly-owned subsidiary Vergence Naturals, which is equipped to provide future cannabinoid-infused products, including perhaps a line of beverages not unlike those that are expected from Canopy and Constellation.
Vergence just recently added to its portfolio the brand Green Tree Therapeutics, known primarily for its brand of vape pens, and currently already being sold in brick and mortar stores, and over 130 outlets in total.
While not a multi-billion-dollar company like that of Aphria Inc. (TSXV: APH) (OTC: APHQF), Canopy Growth (TSX: WEED) (OTC: TWMJF), and MedReleaf Corp. (TSX: LEAF) (OTC: MEDFF), Abattis has strategically positioned itself as an expert in extraction and testing, as well as cannabinoid-infused product marketing.
There is still plenty of room for entities such as Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF) to grow within the cannabis sector that’s still technically in its infancy, as the rollout of legalization finally gets underway.
Aphria is one of Canada’s lowest cost licensed cannabis producers, specializing in the production, suppy, and sale of medical cannabis. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It also provides support services in the form of medical consultations, group therapies, and rehabilitation to veteran and first responders. The company sells its products through its online store or phones, as well as engages in the wholesale shipping of medical marijuana plant cuttings and dried buds to other licensed producers. Aphria Inc. is headquartered in Leamington, Canada.
Formerly known as Tweed Marijuana Inc., Canopy Growth is a multi-licensed, geographically diverse marijuana producer, described as “one of the world’s — and Canada’s first — premier exporters of marijuana” by the Financial Post in 2016. Canopy is the parent company of licensed cannabis producers, Tweed Inc., Tweed Farms Inc., Bedrocan Canada Inc., as well as newly acquired Mettrum Health Corp. Canopy currently has a combined growing platform of over 665,000 sq. ft. of production space. It was also the first federally regulated, publicly traded cannabis producer in North America, and the first billion-dollar cannabis corporation. Canopy Growth was founded in 2014, and is based in Smith Falls, Ontario.
MedReleaf produces and sells cannabis-based pharmaceutical products in Canada. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. MedReleaf was Canada’s first and only ISO 9001 and ICH-GMP certified producer of medical cannabis. It recently announced a joint venture with an Australian partner for cultivation and production of medical cannabis in Australia. The company was incorporated in 2013 and is headquartered in Markham, Canada.
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation.